personalized medicine

Novartis broke ground on a $46K sq. ft. radioligand therapy facility in Texas, the fifth RLT site supporting its $23B US manufacturing investment ending in 2028.

Novartis broke ground on a Texas radioligand therapy facility, the fifth in its US network, part of a $23 billion manufacturing investment expected operational by 2028.

Global DNA microarray market projected to grow from $2.5B in 2025 to $4.7B by 2034 at 7% CAGR, driven by genomic research and personalized medicine demand.

Global stem cell therapy market projected to grow from $21.9B in 2025 to $58.5B by 2034 at 11% CAGR, driven by technological advances and favorable regulations.

Northwest Biotherapeutics appoints experienced biopharma executive Dr. Annalisa Jenkins as Strategic Adviser to advance its DCVax dendritic cell cancer vaccine platform.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

Omics clinical trials market grows 8.8% annually from $31.71B in 2025 to $47.78B by 2030, driven by personalized medicine demand and AI advances.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

Northwest Biotherapeutics establishes dedicated UK leukapheresis clinic by June 2026, enabling scaled immunotherapy production and removing manufacturing bottlenecks.

Evaxion's AI-Immunology platform identifies endogenous retroviruses as glioblastoma vaccine targets, addressing mutational burden challenges. Results presented at AACR in April 2026.

Drug development services market projected to reach $50.26B by 2030 from $28.09B in 2025, driven by AI adoption, personalized medicine, and emerging market expansion.

Global molecular diagnostics market projected to grow from $18.26B in 2025 to $43.50B by 2035, driven by early disease detection demand and advanced technology adoption.

Global oncology biomarkers market projected to grow from $17.3B (2025) to $33.63B (2030) at 14.3% CAGR, driven by AI, liquid biopsies, and precision medicine adoption.

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.

Lamzede market expands globally, led by Europe with fastest growth in Asia-Pacific, driven by rare disease diagnostic advances and enzyme replacement therapy adoption.

Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.

Danish biotech $EVAX will announce full-year 2025 financial results and business update March 5, detailing AI-Immunology platform development across oncology, infectious disease, and autoimmune applications.

Cord blood banking market expected to grow 47% to $49.85B by 2031, driven by expanding stem cell therapies and regenerative medicine applications.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.